# Skin Improvement in Japanese Patients With Inflammatory Dermatologic Conditions Using the Injectable Hyaluronic Acid VYC‐12

## TL;DR

Injectable hyaluronic acid VYC-12 improved skin redness and hydration in Japanese patients with inflammatory skin conditions.

## Contribution

Demonstrates VYC-12's effectiveness in reducing redness and improving hydration in inflammatory dermatologic conditions.

## Key findings

- Skin redness decreased significantly in patients with inflammatory conditions after VYC-12 treatment.
- Stratum corneum moisture levels increased significantly following VYC-12 injections.
- All patients reported satisfaction with the treatment outcomes.

## Abstract

Many skin disorders of the face have an inflammatory element, including atopic dermatitis, acne vulgaris, and rosacea. VYC‐12 is an injectable hyaluronic acid product with well‐established hydrating effects and potential anti‐inflammatory benefits.

To assess the utility of VYC‐12 for improving inflammatory skin conditions.

This was a single‐center, retrospective analysis of adults with a facial inflammatory skin condition that was resistant to standard treatments. A small group was also included who only required treatment for aging‐related concerns. VYC‐12 was injected into the deep dermis based on the standard technique. Imaging was used to assess skin redness and stratum corneum moisture levels. Patient satisfaction was evaluated on a five‐point Likert scale, and adverse events were recorded throughout a mean follow‐up of 4 months.

Fifteen patients were included (86.7% female; mean age: 40.5 ± 9.7 years). Four had atopic dermatitis, 4 had acne vulgaris, and 2 had rosacea; the other 5 had aging‐related dryness and fine lines. Patients received a mean of 3.4 ± 1.2 mL of VYC‐12. Among 10 individuals with an inflammatory skin condition, mean skin redness decreased from 57.7 (arbitrary units) at baseline to 47.9 at 4 months post‐treatment (p < 0.0005); mean stratum corneum moisture levels increased from 45.1 (arbitrary units) to 75.3 over this period (p < 0.0005). All 15 subjects were satisfied with the results. There were no adverse events.

VYC‐12 significantly improved skin redness and hydration in patients with inflammatory skin disorders. Further studies are warranted to assess the benefits of combining VYC‐12 with standard treatments.